Indinavir 400 mg Capsules

A Protease Inhibitor With a Demanding Routine

Our catalog includes Indinavir 400 mg oral capsules in packs of 30 or 60. Indinavir is a first-generation HIV protease inhibitor that must be used with other antiretroviral medicines, not by itself. Its most important practical distinction is the demanding schedule associated with the standard unboosted adult regimen: the usual total dose is 800 mg every 8 hours, which requires two 400 mg capsules at each scheduled dose. Clinician-directed boosted regimens also exist, so the exact dose, timing, and food instructions must come from the prescriber and the labeling for the supplied product.

This is therefore not a medicine to select only by strength or package count. A buyer should already have an established treatment plan that specifies indinavir, the number of capsules per dose, whether a boosting medicine is included, and how indinavir fits with the rest of the HIV regimen. If an every-8-hour routine, food timing, or consistent hydration would be difficult to maintain, that is a meaningful reason to discuss a different antiretroviral option before ordering.

Indinavir's Role in Combination HIV Treatment

The active ingredient is indinavir, and the dosage form in our catalog is an oral capsule containing 400 mg. Indinavir blocks HIV protease, an enzyme the virus uses late in its replication cycle. It was formerly marketed in the United States under the brand name Crixivan; the FDA Drugs@FDA record for Crixivan 400 mg capsules is listed as discontinued. That historical brand record does not establish the regulatory status or manufacturer of another indinavir product.

Indinavir capsules are used as one part of combination antiretroviral therapy. Other medicines in the regimen attack HIV at different stages, helping to maintain viral suppression and reduce the chance that resistance will emerge. A regimen might include medicines from the nucleoside reverse transcriptase inhibitor class, such as lamivudine, which is sold as Epivir, but the complete combination must be chosen by an HIV specialist. Readers comparing options can also review our broader HIV treatment category without assuming that products in the same category are interchangeable.

Who Might Discuss Indinavir With an HIV Care Team?

Indinavir is generally not a preferred starting option in current US HIV treatment because newer regimens are usually easier to take and may have more favorable safety and interaction profiles. It may still arise when an adult is continuing an established regimen or when treatment and resistance history narrows the suitable choices. Factors to review with the care team include:

• Current viral control: whether the existing combination is suppressing HIV and remains appropriate based on laboratory results.
• Treatment and resistance history: whether previous medicines failed, caused adverse effects, or produced resistance that changes the available options.
• Daily routine: whether accurately timed doses, food instructions, and adequate fluid intake are realistic every day.
• Kidney and liver health: whether previous kidney stones, reduced kidney function, liver disease, or other medical issues require closer assessment.
• Other medicines: whether prescription drugs, nonprescription products, or supplements could raise indinavir levels, reduce its effectiveness, or cause a dangerous interaction.
• Pregnancy, breastfeeding, and age: indinavir is not recommended during pregnancy or for children under current US guidance, and people with HIV should discuss current infant-feeding guidance with their care team.

These points help frame a treatment discussion; they do not determine whether indinavir is appropriate for an individual. A prescriber needs the complete clinical picture, including viral load, CD4 count, resistance results, previous adverse effects, and all concurrent medicines.

How Does Indinavir Work?

HIV produces long chains of viral proteins that must be cut into smaller functional pieces before new virus particles can mature. Indinavir binds to HIV protease and interferes with that cutting process. The resulting particles are immature and cannot efficiently infect new cells.

This action does not remove HIV from the body, and indinavir does not prevent infected cells from producing all viral material. It must be combined with other active antiretroviral medicines to suppress replication at more than one point. Maintaining adequate medicine levels is important because missed or irregular doses can allow viral replication to resume and may contribute to resistance. That is why the schedule is a clinical requirement rather than a flexible suggestion.

A Sustainable Dosing and Storage Routine

The prescriber's directions and the supplied product labeling take priority over general guidance. For the standard unboosted adult regimen, commonly cited practical instructions include:

1. Keep doses evenly spaced. A standard schedule of 800 mg every 8 hours means two 400 mg capsules per dose, three times in 24 hours. Set reminders that also work on weekends, during travel, and around work or sleep.
2. Follow the correct food instructions. Unboosted indinavir has traditionally been taken with water on an empty stomach, at least 1 hour before or 2 hours after a meal. A light meal may be permitted under the product directions. Food instructions can differ when indinavir is used in a boosted regimen, so do not transfer instructions from one regimen to another.
3. Maintain adequate hydration. Indinavir can cause kidney stones. Adult labeling has commonly advised drinking at least six 8-fl-oz glasses of liquid over 24 hours. A clinician may need to individualize this advice for someone whose heart, kidney, or other condition limits fluid intake.
4. Do not improvise after a missed dose. Do not double the next dose. Follow the missed-dose directions supplied with the medicine or contact the prescriber or pharmacist if those instructions are unclear.
5. Protect the capsules from moisture. Store them at 59°F to 86°F in the original tightly closed container with the desiccant. Do not swallow the desiccant, and keep the medicine away from children.

Before changing dose times, adding a booster, or altering meal timing, confirm the change with the clinician managing the entire HIV regimen. Adjusting only one component can affect both tolerability and viral suppression.

Available Strength and Package Counts

We offer one strength and dosage form: Indinavir 400 mg capsules for oral use. The available package counts are 30 capsules and 60 capsules. These are package quantities, not automatically a 30-day or 60-day supply. The number of treatment days depends on the prescribed number of capsules per dose and the number of daily doses.

Check the prescription or treatment instructions before selecting a package. If the prescribed regimen uses two capsules three times daily, for example, the package will be used much faster than a medicine taken as one capsule per day. Package choice should account for the prescribed regimen and continuity of treatment rather than package count alone. Do not change the number of capsules taken to make a package last longer.

How Soon Can Treatment Affect Viral Load?

When indinavir is part of a fully active combination and every medicine is taken consistently, laboratory testing may begin to show a falling viral load within the first several weeks. The time needed to reach suppression varies with the starting viral load, treatment history, resistance, the activity of the other medicines, and adherence. A specific result or timeline cannot be guaranteed.

Symptoms are not a reliable way to judge whether treatment is working. Someone may feel well while HIV is not fully suppressed, or may experience temporary adverse effects even while laboratory results improve. Viral-load and CD4 testing at intervals chosen by the HIV care team provides the meaningful evidence. A viral load that does not decline as expected calls for clinical review rather than an unsupervised dose change.

Safety Priorities Before Ordering

Indinavir's safety profile is an important part of the purchase decision. Review the following concerns with the prescriber, especially when any of them already applies:

• Kidney stones and urinary problems: indinavir crystals can form in the urinary tract. Pain in the side or back, blood in the urine, painful urination, or reduced urine output requires prompt medical advice. Adequate hydration lowers risk but does not eliminate it.
• High blood sugar: protease inhibitors, including indinavir, have been associated with new diabetes, worsening diabetes, and high blood sugar. Increased thirst, frequent urination, or unexplained changes in glucose control should be reported.
• Liver and bilirubin changes: indinavir can increase bilirubin and may cause yellowing of the skin or eyes. People with liver disease may require additional assessment and monitoring.
• Bleeding in people with hemophilia: increased bleeding has been reported with protease inhibitors. A hematology or HIV care team should be involved if bleeding changes.
• Allergic reactions: known clinically significant hypersensitivity to indinavir or a capsule component is a reason not to use the product. Facial swelling, breathing difficulty, or a severe rash requires urgent care.
• Dizziness or blurred vision: do not drive or operate machinery until it is clear how the medicine affects alertness and vision.

Pregnancy requires particular attention because indinavir exposure can fall substantially, creating a risk of inadequate viral suppression. Current US perinatal HIV guidance does not recommend indinavir during pregnancy, although this is not described as an absolute contraindication. A person who is pregnant or planning pregnancy should not stop an antiretroviral regimen suddenly; the HIV care team should arrange an effective alternative.

Interactions and Practical Precautions

Indinavir is affected by the CYP3A4 enzyme pathway, which is shared by many medicines. Some combinations can produce dangerously high levels of another drug, while others can reduce indinavir exposure enough to threaten viral suppression. A complete interaction check should cover prescription medicines, over-the-counter products, vitamins, recreational substances, and herbal supplements.

• Cholesterol medicines: some statins can reach unsafe concentrations with protease inhibitors and increase the risk of serious muscle injury. A clinician may choose a different statin or dose.
• Seizure medicines: certain anticonvulsants can reduce protease-inhibitor concentrations and may require a different treatment plan or closer monitoring.
• St. John's wort: this herbal product can substantially lower indinavir exposure and should not be combined with it.
• Sedatives, erectile-dysfunction medicines, and heart medicines: some products in these groups require avoidance, a strict dose limit, or monitoring because indinavir can increase their concentrations.
• Other antiretrovirals: ritonavir and other HIV medicines can change indinavir dosing, food requirements, and adverse-effect risks. Boosting should never be added without explicit instructions.

This list is not exhaustive. Our pharmacist is available 24/7 by email, online chat, or phone to help review potential interactions, but changes to an HIV regimen should also be coordinated with the prescribing clinician.

Which Alternative Might Be More Practical?

The most useful comparison depends on why indinavir is being considered. A person successfully continuing an established regimen faces a different decision from someone selecting a new regimen after resistance, intolerance, or a treatment interruption. Atazanavir and darunavir are protease inhibitors with different dosing schedules, boosting requirements, interaction profiles, and monitoring needs. They may be easier to schedule in some regimens, but neither is automatically suitable for every patient.

Kaletra combines lopinavir with ritonavir, providing a built-in booster and a different dosing and interaction pattern. Older protease inhibitors such as saquinavir, nelfinavir, fosamprenavir, and tipranavir may occasionally enter a specialist discussion based on treatment history, but they should not be treated as simple capsule-for-capsule substitutes. A regimen based on another drug class, such as one containing Nevirapine, creates a different set of resistance, safety, and monitoring considerations.

The comparison elements below summarize conditional differences among relevant options. They are a discussion aid rather than a substitute for resistance testing or individualized prescribing.

US Prescription and Regulatory Context

Indinavir is a prescription-only antiretroviral medicine in the United States. Its prescription status is separate from a pharmacy's technical ordering process: the medicine still requires a prescriber-directed regimen and appropriate HIV monitoring. The FDA record for Crixivan under NDA 020685 is listed as discontinued, and that record does not by itself establish FDA registration for another indinavir capsule product.

Check the labeling and manufacturer information supplied with the dispensed package before use, since directions and inactive ingredients must match the actual product. Serious adverse events and product-quality problems may be reported to FDA MedWatch. Urgent symptoms should be directed to emergency or clinical services rather than handled only as a product-support question.

Ordering and Support From Our Pharmacy

We have operated online since 2010, and our current catalog options for this product are 30 or 60 capsules at the 400 mg strength. Before ordering, compare the package count with the prescribed number of capsules per day, confirm that the treatment plan specifically calls for oral indinavir capsules, and review the timing of the next clinical follow-up. Avoid gaps in an antiretroviral regimen, but do not obtain extra capsules as a reason to continue a regimen that the prescriber has changed.

Our support team is available 24/7 by email, online chat, or phone. A pharmacist can help with questions about the listed strength, package count, storage, or potential interactions. Support can clarify product and medicine information, but it cannot replace the prescriber's selection of the complete HIV regimen or the laboratory monitoring needed to assess it.

A Decision Based on Fit, Not Familiarity

Indinavir 400 mg capsules may be a reasonable option when a specialist has selected indinavir based on treatment history and the patient can follow the prescribed routine reliably. The central practical issue is whether the complete regimen, including dose timing, food instructions, hydration, interaction precautions, and monitoring, is sustainable.

If indinavir is already part of a stable, effective regimen, package selection is mainly a matter of matching the available count to the prescription and treatment plan. If the schedule is difficult, the regimen is being started or changed, pregnancy is possible, or important interactions are present, review alternatives with the HIV care team before finalizing an order.